**Protocol for the Examination of Biopsy Specimens from Patients with Carcinoma of the Urethra and Periurethral Glands**

**Version:** 4.3.0.0

**Protocol Posting Date:** December 2024

The use of this protocol is recommended for clinical care purposes but is not required for accreditation purposes.

**This protocol may be used for the following procedures AND tumor types:**

|  |  |
| --- | --- |
| **Procedure** | **Description** |
| Biopsy | Includes specimens designated biopsy or transurethral resection |
| **Tumor Type** | **Description** |
| Carcinomas | Includes invasive carcinomas of the urinary tract, including urothelial carcinoma and its morphological subtypes, and other carcinomas such as squamous cell carcinoma, adenocarcinoma, Mϋllerian carcinoma, and neuroendocrine carcinoma# |

**The following should NOT be reported using this protocol:**

|  |
| --- |
| **Procedure** |
| Resection (consider the Urethra Resection protocol) |
| Cytologic specimens |

**The following tumor types should NOT be reported using this protocol:**

|  |
| --- |
| **Tumor Type** |
| Lymphoma (consider the Precursor and Mature Lymphoid Malignancies protocol) |
| Sarcoma (consider the Soft Tissue protocol) |
| Melanoma |

**Version Contributors**

**Cancer Committee Authors:** Lara Harik, MD, FCAP\*, Paari Murugan, MD, FCAP\*, Gladell Paner, MD, FCAP\*

**Other Expert Contributors:** Hikmat Al-Ahmadie, MD, Robert Allan, MD, FCAP\*, Donna Hansel, MD, PhD, Giovanna Giannico, MD, Jesse McKenney, MD, Philippe Spiess, MD, Pheroze Tamboli, MD, Toyonori Tsuzuki, MD, Matthew Wasco, MD

\* Denotes primary author.

For any questions or comments, contact: cancerprotocols@cap.org.

**Glossary:**

**Author:** Expert who is a current member of the Cancer Committee, or an expert designated by the chair of the Cancer Committee.

**Expert Contributors:** Includes members of other CAP committees or external subject matter experts who contribute to the current version of the protocol.

**Accreditation Requirements**

The use of this case summary is recommended for clinical care purposes but is not required for accreditation purposes. The core and conditional data elements are routinely reported. Non-core data elements are indicated with a plus sign (+) to allow for reporting information that may be of clinical value.

**Summary of Changes**

**v 4.3.0.0**

* Updated Tumor Extent question

**Reporting Template**

**Protocol Posting Date:** December 2024

**Select a single response unless otherwise indicated.**

**CASE SUMMARY: (URETHRA: Biopsy)**

*This case summary is recommended for reporting biopsy specimens but is not required for accreditation purposes.*

\_\_\_ Urethra

**SPECIMEN (Note** [**A**](#N14316)**)**

**Specimen**

\_\_\_ Urethra

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Not specified

**TUMOR**

**Tumor Site (select all that apply)**

*Male*

\_\_\_ Penile urethra

\_\_\_ Bulbomembranous urethra

\_\_\_ Prostatic urethra

*Female*

\_\_\_ Anterior urethra

\_\_\_ Posterior urethra

*Other*

\_\_\_ Urethra, NOS: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Histologic Type (Note** [**B**](#N14317)**) (select all that apply)**

*Urothelial*

\_\_\_ Papillary urothelial carcinoma, noninvasive

\_\_\_ Papillary urothelial carcinoma, invasive

\_\_\_ Urothelial carcinoma in situ

\_\_\_ Urothelial carcinoma, invasive (conventional)

\_\_\_ Urothelial carcinoma, micropapillary

\_\_\_ Urothelial carcinoma, nested

\_\_\_ Urothelial carcinoma, tubular and microcystic

\_\_\_ Urothelial carcinoma, lymphoepithelioma-like

\_\_\_ Urothelial carcinoma, plasmacytoid

\_\_\_ Urothelial carcinoma, sarcomatoid

\_\_\_ Urothelial carcinoma, giant cell

\_\_\_ Urothelial carcinoma, poorly differentiated

\_\_\_ Urothelial carcinoma, lipid-rich

\_\_\_ Urothelial carcinoma, clear cell (glycogen-rich)

\_\_\_ Urothelial carcinoma with squamous differentiation

\_\_\_ Urothelial carcinoma with glandular differentiation

\_\_\_ Urothelial carcinoma with trophoblastic differentiation

\_\_\_ Urothelial carcinoma with Müllerian differentiation

*Squamous*

\_\_\_ Squamous cell carcinoma

\_\_\_ Verrucous carcinoma

\_\_\_ Squamous cell carcinoma in situ (no invasive carcinoma identified)

\_\_\_ HPV-associated squamous cell carcinoma

*Glandular*

\_\_\_ Adenocarcinoma, NOS

\_\_\_ Adenocarcinoma, enteric

\_\_\_ Adenocarcinoma, mixed

\_\_\_ Adenocarcinoma, mucinous

\_\_\_ Adenocarcinoma, signet-ring cell

\_\_\_ Adenocarcinoma in situ (no invasive carcinoma identified)

*Müllerian*

\_\_\_ Clear cell adenocarcinoma

\_\_\_ Endometrioid carcinoma

*Neuroendocrine*

\_\_\_ Small cell neuroendocrine carcinoma

\_\_\_ Large cell neuroendocrine carcinoma

\_\_\_ Well-differentiated neuroendocrine tumor

*Other*

\_\_\_ Littre gland adenocarcinoma

\_\_\_ Skene gland adenocarcinoma

\_\_\_ Cowper gland adenocarcinoma

\_\_\_ Other histologic type not listed (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Carcinoma, type cannot be determined: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**+Specify Percentages of Histologic Subtypes and Divergent Differentiations Present (totaling 100%)#  (select all that apply)**

*# Applicable for mixed subtypes, divergent differentiations, and other carcinomas*

\_\_\_ Urothelial carcinoma, invasive (conventional): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ %

\_\_\_ Urothelial carcinoma, micropapillary: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ %

\_\_\_ Urothelial carcinoma, nested: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ %

\_\_\_ Urothelial carcinoma, large nested: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ %

\_\_\_ Urothelial carcinoma, tubular and microcystic: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ %

\_\_\_ Urothelial carcinoma, lymphoepithelioma-like: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ %

\_\_\_ Urothelial carcinoma, plasmacytoid: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ %

\_\_\_ Urothelial carcinoma, sarcomatoid: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ %

\_\_\_ Urothelial carcinoma, giant cell: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ %

\_\_\_ Urothelial carcinoma, poorly differentiated: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ %

\_\_\_ Urothelial carcinoma, lipid-rich: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ %

\_\_\_ Clear cell (glycogen-rich): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ %

\_\_\_ Squamous differentiation: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ %

\_\_\_ Glandular (adenocarcinoma) differentiation: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ %

\_\_\_ Trophoblastic differentiation: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ %

\_\_\_ Müllerian differentiation: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ %

\_\_\_ Small cell neuroendocrine carcinoma: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ %

\_\_\_ Large cell neuroendocrine carcinoma: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ %

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**+Histologic Type Comment: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

**Histologic Grade (Note** [**C**](#N14318)**)**

*For urothelial carcinoma, other subtypes, or divergent differentiation*

\_\_\_ Low-grade

\_\_\_ High-grade

*For squamous cell carcinoma or adenocarcinoma*

\_\_\_ G1, well-differentiated

\_\_\_ G2, moderately differentiated

\_\_\_ G3, poorly differentiated

\_\_\_ GX, cannot be assessed: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

*Other*

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cannot be assessed: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Not applicable: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Tumor Extent (Note** [**D**](#N14319)**)**

*Male*

\_\_\_ Carcinoma of penile and bulbomembranous urethra

\_\_\_ Noninvasive urothelial papillary carcinoma

\_\_\_ Carcinoma in situ

\_\_\_ Invades subepithelial connective tissue

\_\_\_ Invades adjacent structure(s)

\_\_\_ Corpus spongiosum

\_\_\_ Periurethral muscle

\_\_\_ Tunica albuginea

\_\_\_ Corpus cavernosum

\_\_\_ Scrotum

\_\_\_ Urinary bladder wall

\_\_\_ Rectum

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Carcinoma of prostatic urethra

\_\_\_ Noninvasive urothelial papillary carcinoma

\_\_\_ Carcinoma in situ, involving prostatic urethra

\_\_\_ Carcinoma in situ, involving prostatic ducts

\_\_\_ Invades urethral subepithelial connective tissue immediately underlying the urothelium

\_\_\_ Invades prostatic stroma surrounding ducts either by direct extension from the urothelial surface or

 by invasion from prostatic ducts

\_\_\_ Invades periprostatic fat

\_\_\_ Invades adjacent structure(s)

\_\_\_ Extraprostatic invasion of the bladder wall

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

*Female*

\_\_\_ Noninvasive urothelial papillary carcinoma

\_\_\_ Carcinoma in situ

\_\_\_ Invades subepithelial connective tissue

\_\_\_ Invades adjacent structure(s)

\_\_\_ Periurethral muscle (fibromuscular and adipose tissue)

\_\_\_ Anterior vagina

\_\_\_ Urinary bladder wall

\_\_\_ Rectum

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

*Other*

\_\_\_ Cannot be determined: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ No evidence of primary tumor

**+Lymphatic and / or Vascular Invasion**

\_\_\_ Not identified

\_\_\_ Present

\_\_\_ Cannot be determined: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**+Tumor Configuration (select all that apply)**

\_\_\_ Papillary

\_\_\_ Solid / nodule

\_\_\_ Flat

\_\_\_ Ulcerated

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cannot be determined: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**+Tumor Comment: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

**ADDITIONAL FINDINGS**

**+Associated Epithelial Lesions (select all that apply)**

\_\_\_ None identified

\_\_\_ Condyloma acuminata

\_\_\_ Squamous dysplasia (low, intermediate, high grade)

\_\_\_ Urothelial papilloma

\_\_\_ Urothelial papilloma, inverted type

\_\_\_ Papillary urothelial neoplasm, low malignant potential (PUNLMP)

\_\_\_ Urothelial dysplasia

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cannot be determined: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**+Additional Findings (select all that apply)**

\_\_\_ Keratinizing squamous metaplasia

\_\_\_ Inflammation / regenerative changes

\_\_\_ Therapy-related changes (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cautery artifact

\_\_\_ Urethritis cystica et glandularis

\_\_\_ Intestinal metaplasia

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**COMMENTS**

**Comment(s): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

**Explanatory Notes**

**A. History**

A relevant history is important for the interpretation of urethral biopsies. A history of renal stones, recent urinary tract procedures, infections, obstruction, or prior therapy (intravesical or systemic chemotherapy, local radiation) can lead to reactive epithelial changes potentially mimicking malignancy. Any neoplasms previously diagnosed should be specified, including the histologic type, primary site, and histologic grade.

**B. Histologic Type**

Carcinomas of the urethra vary in histologic type, depending on type of epithelium lining the urethra in a given anatomic location.[1,](#R67428)[2,](#R67429)[3,](#R67430)[4](#R67431) In women, squamous cell carcinoma is the most common histologic subtype (approximately 75%) and is most common in the anterior urethra (distal third). Urothelial carcinoma is next in frequency, followed by adenocarcinoma (approximately 10% to 15% each). Clear cell adenocarcinomas comprise a significant proportion of adenocarcinomas in women but are quite rare in men. In the male, most tumors involve the bulbomembranous urethra, followed by penile urethra and prostatic urethra. Most carcinomas of the male urethra (80%) are squamous cell carcinoma, followed by urothelial origin. As in women, urothelial carcinomas are typically more proximal. Primary urethral adenocarcinomas are rare in men. Adenocarcinomas may rarely arise from the periurethral Skene’s (female) or Littre’s (male) glands. The distinction between a urothelial carcinoma with divergent squamous, glandular, or Müllerian differentiation and a pure squamous cell carcinoma, adenocarcinoma or Müllerian should be made. The 2022 World Health Organization (WHO) classification, require a pure histology of squamous cell carcinoma, adenocarcinoma, or Müllerian to designate a tumor as such, all others with recognizable papillary, invasive, or flat carcinoma in situ (CIS) urothelial component being considered as urothelial carcinoma with divergent differentiation.

**2022 WHO Classification of Epithelial Tumors of the Urothelial Tract**

Urothelial tumors

*Invasive urothelial carcinoma*

Conventional urothelial carcinoma

Urothelial carcinoma with squamous differentiation

Urothelial carcinoma with glandular differentiation

Urothelial carcinoma with trophoblastic differentiation

Nested urothelial carcinoma

Tubular and microcystic urothelial carcinomas

Micropapillary urothelial carcinoma

Lymphoepithelioma-like urothelial carcinoma

Plasmacytoid urothelial carcinoma

Giant cell urothelial carcinoma

Lipid-rich urothelial carcinoma

Clear cell (glycogen-rich) urothelial carcinoma

Urothelial carcinoma, poorly differentiated

*Noninvasive urothelial lesions*

Urothelial carcinoma in situ

Noninvasive papillary urothelial carcinoma, high grade

Noninvasive papillary urothelial carcinoma, low grade

Papillary urothelial neoplasm of low malignant potential

Urothelial papilloma

Inverted urothelial papilloma

Squamous cell neoplasms

Squamous cell carcinoma

Verrucous carcinoma

Squamous papilloma

Glandular neoplasms

Adenocarcinoma, NOS

Enteric

Mucinous

Mixed

Signet-ring cell

Adenocarcinoma in situ

Villous adenoma

Urachal and diverticular neoplasms

Urachal carcinoma

Diverticular carcinoma

Tumors of Mullerian type

Clear cell adenocarcinoma

Endometrioid carcinoma

Neuroendocrine neoplasms

Small cell neuroendocrine carcinoma

Large cell neuroendocrine carcinoma

Mixed neuroendocrine neoplasm

Well-differentiated neuroendocrine tumor

Paraganglioma

Urethral accessory glands

Carcinoma of Littre glands

Carcinoma of Skene glands

Carcinoma of Cowper glands

References

1. WHO Classification of Tumours Editorial Board. Tumours of the urinary tract. In: WHO Classification of Tumours. Urinary and male genital tumours. 5th edition. Geneva, Switzerland: WHO Press; 2022.
2. Moch H, Humphrey PA, Ulbright TM, Reuter VE. WHO Classification of Tumours of the Urinary System and Male Genital Organs. Geneva, Switzerland: WHO Press; 2016.
3. Lopez-Beltran A, Sauter G, Gasser T, et al. Infiltrating urothelial carcinoma. In: Eble JN, Sauter G, Epstein JI, Sesterhenn IA, eds. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon, France: IARC Press; 2004:97.
4. Murphy WM, Grignon DJ, Perlman EJ. Tumors of the kidney, bladder, and related urinary structures. In: Atlas of Tumor Pathology. 4th series. Fascicle 1. Washington, DC: American Registry of Pathology; 2004.

**C. Histologic Grade**

Squamous cell carcinoma and adenocarcinoma are graded on a 3-tiered system that is based on tumor differentiation as well differentiated (grade 1), moderately differentiated (grade 2), or poorly differentiated (grade 3).[1,](#R67422)[2](#R67423)

For urothelial neoplasia, flat intraepithelial lesions and papillary and invasive lesions are graded separately.[1,](#R67422)[3,](#R67424)[4,](#R67425)[5,](#R67426)[6](#R67427) A more universally acceptable system, the World Health Organization/International Society of Urological Pathology (WHO/ISUP) consensus classification, was proposed in 1998 by ISUP and has been adopted in the 2004 WHO classification system and has been validated by many studies to be prognostically significant. This grading system has also been upheld in the 2016 and 2022 WHO classifications with slight modifications. Other systems (that were being used previously) may still be used according to institutional preferences. Tumor grade according to both the 2004 WHO/ISUP system and the older 1973 WHO system may be concurrently used.

References

1. WHO Classification of Tumours Editorial Board. Tumours of the urinary tract. In: WHO Classification of Tumours. Urinary and male genital tumours. 5th edition. Geneva, Switzerland: WHO Press; 2022.
2. Paner GP, Kamat, Netto GJ, et al. International Society of Urological Pathology (ISUP) Consensus Conference on Current Issues in Bladder Cancer. Working Group 2: grading of mixed grade, invasive urothelial carcinoma including histologic subtypes and divergent differentiations, and non-urothelial carcinomas. Am J Surg Pathol. 2023; online ahead of print.
3. Moch H, Humphrey PA, Ulbright TM, Reuter VE. WHO Classification of Tumours of the Urinary System and Male Genital Organs. Geneva, Switzerland: WHO Press; 2016.
4. Sauter G, Algaba F, Amin MB, et al. Non-invasive urothelial tumours. In: Eble JN, Sauter G, Epstein JI, Sesterhenn IA, eds. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon, France: IARC Press; 2004:110.
5. Epstein JI, Amin MB, Reuter VR, Mostofi FK, the Bladder Consensus Conference Committee. The World Health Organization/ International Society of Urological Pathology Consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Am J Surg Pathol. 1998;22(12):1435-1448.
6. Mostofi FK. Histological typing of urinary bladder tumours. In: WHO Histological Classification of Tumours. No. 10. Geneva, Switzerland: World Health Organization; 1973.

**D. Extent of Invasion**

A critical role of the surgical pathologist is to diagnose the depth/extent of invasion into the tissues surrounding the urethra.[1](#R67420) The surrounding anatomic structures vary by gender and location within the urethra and may include at least the subepithelial connective tissue, periurethral muscle, prostate, and corpus spongiosum in transurethral resection specimens.  Identification of these anatomic landmarks and documentation of their tumor involvement is important. In the prostatic urethra, invasion may arise from a tumor lining the urethral lumen or from carcinoma in situ colonizing prostatic ducts. The T1 designation should only be applied to superficial invasion arising from the urethral lining; invasion arising from the prostatic ducts into the prostatic stroma is designated as T2. A urethral urothelial carcinoma may occur concurrently with bladder urothelial carcinoma, thus, prostatic tumor involvement in urethral transurethral resections should not be automatically considered as transmural bladder extension by bladder cancer.

References

1. Amin MB, Edge SB, Greene FL, et al., eds. AJCC Cancer Staging Manual. 8th ed. New York, NY: Springer; 2017.